BlackRock, Inc. 13D and 13G filings for C4 Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | C4 Therapeutics, Inc. CCCC | BlackRock Inc. BLK | 4,891,379 7.100% | 0 (Unchanged) | Filing |
| 2024-10-22 6:06 pm Purchase | 2024-09-30 | 13G | C4 Therapeutics, Inc. CCCC | BlackRock Inc. BLK | 4,891,379 7.100% | 2,804,816 (+134.42%) | Filing |
| 2023-07-07 4:35 pm Sale | 2023-06-30 | 13G | C4 Therapeutics, Inc. CCCC | BlackRock Inc. BLK | 2,086,563 4.300% | -1,534,570 (-42.38%) | Filing |
| 2023-01-31 1:58 pm Purchase | 2022-12-31 | 13G | C4 Therapeutics, Inc. CCCC | BlackRock Inc. BLK | 3,621,133 7.400% | 215,151 (+6.32%) | Filing |
| 2022-02-04 4:12 pm Purchase | 2021-12-31 | 13G | C4 Therapeutics, Inc. CCCC | BlackRock Inc. BLK | 3,405,982 7.000% | 3,405,982 (New Position) | Filing |